NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Other languages Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-07 EDT			5-day change	1st Jan Change
13.5 ^CNY	-1.39%		-1.46%	-10.00%

05-01	NKFPharma Gets Nod to Register New Cancer Treatment	MT
04-27	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NKFPharma Gets Nod to Register New Cancer Treatment	05-01
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-27
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	01-16
NKFPharma Gets Certificate to Register Voriconazole for Injection	01-11
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	12-28
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	12-22
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	23-09-21
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	23-08-17
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	23-07-26
NKFPharma Unit Gets US FDA Nod for Cancer Drug	23-07-21
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	23-06-27
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	23-05-10
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
NKFPharma Gets Certification for Lung Cancer Drug	23-04-11
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	23-02-21
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	22-12-15
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28
King-Friend Biochemical Wins FDA Nod to Market Cancer Treatment in US	22-09-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Other languages

Filters